ART: Advancing Revolutionary Therapies Podcast
Bringing a novel therapeutic to market is an ART. Hear Veristat thought leaders as they draw on their specialized expertise to offer insight on timely, relevant topics that impact clinical development, the regulatory landscape, and patient access to these novel therapies.
Our focus on novel drug development has led to success when handling the unknowns that arise across complicated therapeutic areas, such as rare/ultra-rare disease, advanced therapies, oncology, and infectious disease trials. Whether you’re just starting out— or have deep clinical development expertise— there is always something new to learn.
There are no featured podcasts.
Mar 31, 2023
Feb 10, 2023
Dec 30, 2022
Dec 14, 2022
Nov 30, 2022
Nov 10, 2022
Oct 28, 2022
Sep 22, 2022
Sep 6, 2022
Jun 1, 2022
May 11, 2022
Apr 26, 2022
Apr 12, 2022
Mar 29, 2022
Mar 16, 2022
Mar 2, 2022
If you are wondering how natural history studies are relevant to cell and gene therapy development, listen as Chris Kenwood, Principal Statistician with Veristat, ...
Feb 16, 2022
Developing a successful marketing application involves several strategic steps, as described by Kevin Hennegan, Senior Regulatory Strategist for Veristat. Listen as ...
Dec 16, 2021
The pros, cons and future of allogeneic versus autologous therapies are explored as Rachel Smith, Portfolio Director for ...
Nov 17, 2021
Post-marketing requirements within the European submission process offer conditional approval more flexible than FDA. Rachel Smith, Portfolio Director for Veristat, ...
Nov 6, 2021
The selection of endpoints for a clinical trial relies on clinical relevance combined with statistical reasoning. Robin Bliss, VP of Strategic Consulting for ...
Oct 21, 2021
Aug 12, 2021
Scaling up from phase 1 to global phase II/III trials to beyond marketing approval has several implications on a sponsor’s commercial strategy. Hear from Rachel ...
Jul 15, 2021
Jul 1, 2021